Jaypirca® (pirtobrutinib) – New indication
December 1, 2023 - Eli Lilly announced the FDA approval of Jaypirca (pirtobrutinib), for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Top